Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer

To determine the optimal number of cycles of docetaxel for metastatic castration-resistant prostate cancer, we retrospectively collected 73 patients receiving varying numbers of docetaxel plus prednisolone and analyzed the clinical outcomes including overall survival, prostate-specific antigen (PSA)...

Full description

Bibliographic Details
Main Authors:	Yuan-Chi Shen, Po-Hui Chiang, Hao-Lun Luo, Yao-Chi Chuang, Yen-Ta Chen, Chih-Hsiung Kang, Chun-Chien Hsu, Wei-Ching Lee, Yuan-Tso Cheng
Format:	Article
Language:	English
Published:	Wiley 2016-09-01
Series:	Kaohsiung Journal of Medical Sciences
Subjects:	Chemotherapy Docetaxel Flare-up phenomenon Metastatic castration resistant prostate cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S1607551X16301322

Similar Items

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
by: Nicholas D. James, et al.
Published: (2022-11-01)

Surface-enhanced Raman spectroscopy of serum predicts sensitivity to docetaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
by: Jianian Hu, et al.
Published: (2021-07-01)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
by: Rebeca Lozano, et al.
Published: (2021-05-01)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
by: Judith Passildas‐Jahanmohan, et al.
Published: (2021-04-01)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
by: Sang Eun Yoon, et al.
Published: (2019-05-01)

Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
by: Li-Wen Chang, et al.
Published: (2021-01-01)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
by: Wei Ning, et al.
Published: (2023-09-01)

Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
by: M. I. Volkova, et al.
Published: (2019-06-01)

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study
by: María José Juan Fita, et al.
Published: (2023-10-01)

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
by: Junru Chen, et al.
Published: (2022-01-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
by: Leandro Blas, et al.
Published: (2022-01-01)

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
by: Angelyn Anton, et al.
Published: (2022-05-01)

Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01)

Current problems in the first-line treatment of metastatic breast cancer: focus on the role of docetaxel
by: Filippo Montemurro
Published: (2010-09-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
by: Abhenil Mittal, et al.
Published: (2023-04-01)

Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer
by: Darren M.C. Poon, et al.
Published: (2015-06-01)

Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
by: Thiago S. Lima, et al.
Published: (2022-06-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-04-01)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
by: Meagher MF, et al.
Published: (2023-11-01)

A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
by: A. V. Kondrashina, et al.
Published: (2018-05-01)

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
by: Seonggyu Byeon, et al.
Published: (2020-11-01)

Role of chemotherapy in prostate cancer
by: Rita Nader, et al.
Published: (2018-01-01)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
by: Ietsen de Groot, et al.
Published: (2021-11-01)

Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study
by: Shuya Kandori, et al.
Published: (2016-12-01)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Lixin Mai, et al.
Published: (2020-12-01)

Treatment of Hormone Resistance with Docetaxel in Metastatic Prostate Cancer Patients: Results of a Clinical Experience at Omid Hospital, Isfahan, Iran
by: Mina Tajvidi, et al.
Published: (2017-01-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

Current management of metastatic castration-sensitive prostate cancer
by: Adam Kessel, et al.
Published: (2021-01-01)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
by: Kai-Jie Wu, et al.
Published: (2018-01-01)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
by: Naiki T, et al.
Published: (2018-09-01)

CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2016-12-01)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
by: Stefano Kim, et al.
Published: (2017-08-01)

Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer
by: Rafael A. Kaliks, et al.
Published: (2010-06-01)

Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients
by: LIU Sanhe, et al.
Published: (2019-06-01)

Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
by: Luc Cabel, et al.
Published: (2017-04-01)

Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
by: Hao Xiang Chen, et al.
Published: (2023-07-01)